Novobiocin sensitizes BCRP/MXR/ABCP overexpressing topotecan-resistant human breast carcinoma cells to topotecan and mitoxantrone

Anticancer Research

Volumn 23, Issue 3 B, 2003, Pages 2519-2523

  Yang, Chih Hsin ^a,b   Chen, Yao Chang ^b   Kuo, Min Liang ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

BCRP; Mitoxantrone; Multidrug resistance; Novobiocin; Topotecan

Indexed keywords

BCRP PROTEIN; BREAST CANCER RESISTANCE PROTEIN; GENE PRODUCT; MITOXANTRONE; NOVOBIOCIN; SULFORHODAMINE B; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TRANSPORT; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL LINE;

ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MITOXANTRONE; NEOPLASM PROTEINS; NOVOBIOCIN; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0042807572     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V and Dean MA: Human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res 58: 5337-5339, 1998.
2. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U.S.A. 95: 15665-15670, 1998.
3. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T and Bates SE: Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res 59: 8-13, 1999.
4. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP and Doyle LA: A typical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Ins 91: 429-433, 1999.
5. Kawabata S, Oka M, Shiozawa K, Tsukamoto K, Nakatomi K, Soda H, Fukuda M, Ikegami Y, Sugahara K, Yamada Y, Kamihira S, Doyle LA, Ross DD and Kohno S: Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem Bioph Res Co 280: 1216-1223, 2001.
6. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoto M, Arakawa H and Nishimura S: Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure. Cancer Res 61: 2827-2832, 2001.
7. Allen JD, Brinkhuis RF, Wijnholds J and Schinkel AH: The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59: 4237-4241, 1999.
8. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59: 4559-4563, 1999.
9. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E and Chen YC: BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 60: 831-837, 2000.
10. Schellens JH, Maliepaard M, Scheper RJ, Scheffer GL, Jonker JW, Smit JW, Beijnen JH and Schinkel AH: Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications. Annals NY Acad Sci 922: 188-194, 2000.
11. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer I 182: 1107-1112, 1990.
12. Hendricks CB, Rowinsky EK, Grochow LB, Donehower RC and Kaufmann SH: Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 52: 2268-2278, 1992.
13. Eder JP, Teicher BA, Holden SA, Cathcart KN and Schnipper L: Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest 79: 1524-1528, 1987.
14. Lorico A, Rappa G and Sartorelli AC: Novobiocin-induced accumulation of etoposide (VP-16) in WEHI-3B D+ leukemia cells. Int J Cancer 52: 903-909, 1992
15. Downes CS, Ord MJ, Mullinger AM, Collins AR and Johnson R: Novobiocin inhibition of DNA excision repair may occur through effects on mitochondrial structure and ATP metabolism, not on repair topoisomerases. Carcinogenesis 6: 1343-1352, 1985.
16. Rocchi E, Khodjakov A, Volk EL, Yang CH, Litman T, Bates SE and Schneider E: The product of the ABC half-transporter gene ABCG2 (BCRP/MXR/ABCP) is expressed in the plasma membrane. Biochem Bioph Res Co 271: 42-46, 2000.
17. Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL and Davidson NE: Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 13: 1136-1143, 1995.
18. Eder JP, Wheeler CA, Teicher BA and Schnipper LE: A phase I clinical trial of novobiocin, a modulator of alkylating agent cytotoxicity. Cancer Res 51: 510-513, 1991.
19. Rabindran SK, Ross DD, Doyle LA, Yang W and Greenberger LM: Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60: 47-50, 2000.
20. Ross DD, Karp JE, Chen TT and Doyle LA: Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96: 365-368, 2000.